# EDGAR Filing Document

**Accession Number:** 0001395064
**File Stem:** 0001395064-26-000187
**Filing Date:** 2026-6
**Character Count:** 7307
**Document Hash:** fdda3a2c2edaf980f199ae042a4d38a2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001395064-26-000187.hdr.sgml**: 20260626

**ACCESSION NUMBER**: 0001395064-26-000187

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 5

**CONFORMED PERIOD OF REPORT**: 20260626

**FILED AS OF DATE**: 20260626

**DATE AS OF CHANGE**: 20260626

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** TAKEDA PHARMACEUTICAL CO LTD
- **CENTRAL INDEX KEY:** 0001395064
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38757
- **FILM NUMBER:** 261123795

**BUSINESS ADDRESS:**
- **STREET 1:** 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU
- **CITY:** TOKYO
- **STATE:** M0
- **ZIP:** 103-8668
- **BUSINESS PHONE:** 81332782111

**MAIL ADDRESS:**
- **STREET 1:** 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU
- **CITY:** TOKYO
- **STATE:** M0
- **ZIP:** 103-8668

**FORM 6-K**

**U.S. SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Report of Foreign Private Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of**

**the Securities Exchange Act of 1934**

**For the month of June 2026**

**Commission File Number: 001-38757**

**TAKEDA PHARMACEUTICAL COMPANY LIMITED**

**(Translation of registrant's name into English)**

**1-1, Nihonbashi-Honcho 2-Chome**

**Chuo-ku, Tokyo 103-8668**

**Japan**

**(Address of principal executive offices)**

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

------

Information furnished on this form:

**EXHIBIT**

---

| | |
|:---|:---|
| Exhibit<br>Number | |
| 99.1 | <u>[Results of the Exercise of Voting Rights of the 150th Annual General Meeting of Shareholders](extraordinary_report.htm)</u> |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **TAKEDA PHARMACEUTICAL COMPANY LIMITED** | **TAKEDA PHARMACEUTICAL COMPANY LIMITED** |
| Date: June 26, 2026 | By: | /s/ Norimasa Takeda |
|  |  | Norimasa Takeda<br>Chief Accounting Officer and Corporate Controller |

---

## Exhibit 99.1

![](extraordinary_report001.jpg)

Results of the Exercise of Voting Rights of the 150th Annual General Meeting of Shareholders 1. Reason for the submission The report is submitted pursuant to the provisions of Article 24-5, Paragraph 4 in the Financial Instruments and Exchange Act, and Article 19, Paragraph 2, Item 9-2 in the Cabinet Office Ordinance on Disclosure of Corporate Information, etc., which shows the results of the resolution on the items to be resolved at the 150th Annual General Meeting of Shareholders of the Company held on June 24, 2026. 2. Contents [1] The date of the shareholders meeting June 24, 2026 [2] Details of items to be resolved Proposal No.1: Appropriation of Surplus Concerning the year-end dividend 100 JPY per share of common stock of the Company Proposal No.2: Election of Eight (8) Directors who are not Audit and Supervisory Committee Members To elect Julie Kim, Milano Furuta, Andrew Plump, Masami Iijima, Steven Gillis, John Maraganore, Miki Tsusaka and Paul Stoffels as Directors who are not Audit and Supervisory Committee Members. Proposal No.3: Election of Three (3) Directors who are Audit and Supervisory Committee Members To elect Kimberly A. Reed, Bruce Broussard and Koichiro Kimura as Directors who are Audit and Supervisory Committee Members. Proposal No.4: Election of One (1) Substitute Director who is an Audit and Supervisory Committee Member To elect Paul Stoffels as a Substitute Director who is an Audit and Supervisory Committee Member. Proposal No.5: Payment of Bonuses to Directors who are not Audit and Supervisory Committee Members To pay bonuses within a total of 260 million JPY to the 2 Directors who are not Audit and Supervisory Committee Members (excluding Directors residing outside of Japan and External Directors) in office as of the end of this fiscal year.

------

![](extraordinary_report002.jpg)

[3] Numbers of voting rights for approval of, against and abstaining from each of the items to be resolved, requirements for each of the items to be resolved to be approved and the results for each resolution Item to be resolved Approval (No. of voting rights) Against (No. of voting rights) Abstention (No. of voting rights) Total No. of voting rights exercised Result (Proportion of approval) Approval requirements Proposal No.1 11,994,528 2,199 25 12,183,048 Approval (98.45%) (Note) 1 Proposal No.2 (Note) 2 Julie Kim 11,840,220 223,449 9,105 12,183,109 Approval (97.19%) Milano Furuta 11,392,485 679,968 25 12,182,813 Approval (93.51%) Andrew Plump 11,274,783 797,914 25 12,183,057 Approval (92.54%) Masami Iijima 11,584,361 488,316 25 12,183,037 Approval (95.09%) Steven Gillis 11,619,791 452,859 25 12,183,010 Approval (95.38%) John Maraganore 11,571,136 501,534 25 12,183,030 Approval (94.98%) Miki Tsusaka 11,603,016 469,663 25 12,183,039 Approval (95.24%) Paul Stoffels 11,962,283 110,380 25 12,183,023 Approval (98.19%) Proposal No.3 (Note) 2 Kimberly A. Reed 11,659,554 412,957 25 12,183,027 Approval (95.70%) Bruce Broussard 11,184,764 887,743 25 12,183,023 Approval (91.81%) Koichiro Kimura 11,963,428 109,105 25 12,183,049 Approval (98.20%) Proposal No.4 (Note) 2 Paul Stoffels 11,999,993 72,670 25 12,183,025 Approval (98.50%) Proposal No.5 10,104,535 1,946,260 21,968 12,183,074 Approval (82.94%) (Note) 1 (Note) 1. Approval requires a majority of the voting rights of shareholders in attendance and able to exercise voting rights. 2. Approval requires the attendance of shareholders possessing at least one third of the voting rights of shareholders who are able to exercise voting rights and a majority of the voting rights of shareholders in attendance.

------

![](extraordinary_report003.jpg)

[4] Reason for not adding some of the voting rights of shareholders who attended the Annual General Meeting of Shareholders to the number of voting rights for approval of, against or abstaining from each of the items to be resolved The requirements for approval of the resolutions were met by the advance voting by the day prior to the date of this Annual General Meeting of Shareholders and the tallying of votes received from some of the shareholders who attended on the day of the meeting for which the approval or otherwise of the resolutions could be confirmed, and the resolutions were thus passed legally in accordance with the Companies Act. Therefore, the remaining votes of shareholders who attended on the day of this Annual General Meeting of Shareholders were not added to the number of voting rights for approval of, against or abstaining from each of the items to be resolved. End of Document

------